Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging
The beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in people with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) have been suggested in several reports based on serological markers, imaging data, and histopathology associated with...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2024-08-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/8/71_EJ24-0005/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591885277855744 |
|---|---|
| author | Agena Suzuki Akinori Hayashi Satoshi Oda Rei Fujishima Naoya Shimizu Kenta Matoba Tomomi Taguchi Takuya Toki Takeshi Miyatsuka |
| author_facet | Agena Suzuki Akinori Hayashi Satoshi Oda Rei Fujishima Naoya Shimizu Kenta Matoba Tomomi Taguchi Takuya Toki Takeshi Miyatsuka |
| author_sort | Agena Suzuki |
| collection | DOAJ |
| description | The beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in people with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) have been suggested in several reports based on serological markers, imaging data, and histopathology associated with steatotic liver disease. However, evidence regarding their long-term effects is currently insufficient. In this retrospective observational study, 34 people with T2D and MASLD, treated with SGLT2 inhibitors, were examined by proton density fat fraction derived by magnetic resonance imaging (MRI-PDFF) and other clinical data before, one year after the treatment. Furthermore, 22 of 34 participants underwent MRI-PDFF five years after SGLT2 inhibitors were initiated. HbA1c decreased from 8.9 ± 1.8% to 7.8 ± 1.0% at 1 year (p = 0.006) and 8.0 ± 1.1% at 5 years (p = 0.122). Body weight and fat mass significantly reduced from baseline to 1 and 5 year(s), respectively. MRI-PDFF significantly decreased from 15.3 ± 7.8% at baseline to 11.9 ± 7.6% (p = 0.001) at 1 year and further decreased to 11.3 ± 5.7% (p = 0.013) at 5 years. Thus, a 5-year observation demonstrated that SGLT2 inhibitors have beneficial effects on liver steatosis in people with T2D and MASLD. |
| format | Article |
| id | doaj-art-00f5eb93060f4668a8fda6c2d44d6ba1 |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-00f5eb93060f4668a8fda6c2d44d6ba12025-01-22T05:14:15ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402024-08-0171876777510.1507/endocrj.EJ24-0005endocrjProlonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imagingAgena Suzuki0Akinori Hayashi1Satoshi Oda2Rei Fujishima3Naoya Shimizu4Kenta Matoba5Tomomi Taguchi6Takuya Toki7Takeshi Miyatsuka8Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanDepartment of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, JapanThe beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in people with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) have been suggested in several reports based on serological markers, imaging data, and histopathology associated with steatotic liver disease. However, evidence regarding their long-term effects is currently insufficient. In this retrospective observational study, 34 people with T2D and MASLD, treated with SGLT2 inhibitors, were examined by proton density fat fraction derived by magnetic resonance imaging (MRI-PDFF) and other clinical data before, one year after the treatment. Furthermore, 22 of 34 participants underwent MRI-PDFF five years after SGLT2 inhibitors were initiated. HbA1c decreased from 8.9 ± 1.8% to 7.8 ± 1.0% at 1 year (p = 0.006) and 8.0 ± 1.1% at 5 years (p = 0.122). Body weight and fat mass significantly reduced from baseline to 1 and 5 year(s), respectively. MRI-PDFF significantly decreased from 15.3 ± 7.8% at baseline to 11.9 ± 7.6% (p = 0.001) at 1 year and further decreased to 11.3 ± 5.7% (p = 0.013) at 5 years. Thus, a 5-year observation demonstrated that SGLT2 inhibitors have beneficial effects on liver steatosis in people with T2D and MASLD.https://www.jstage.jst.go.jp/article/endocrj/71/8/71_EJ24-0005/_html/-char/entype 2 diabetes mellitussodium-glucose cotransporter 2 inhibitormetabolic dysfunction-associated steatotic liver diseasemagnetic resonance imaging-derived proton density fat fraction |
| spellingShingle | Agena Suzuki Akinori Hayashi Satoshi Oda Rei Fujishima Naoya Shimizu Kenta Matoba Tomomi Taguchi Takuya Toki Takeshi Miyatsuka Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging Endocrine Journal type 2 diabetes mellitus sodium-glucose cotransporter 2 inhibitor metabolic dysfunction-associated steatotic liver disease magnetic resonance imaging-derived proton density fat fraction |
| title | Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging |
| title_full | Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging |
| title_fullStr | Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging |
| title_full_unstemmed | Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging |
| title_short | Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging |
| title_sort | prolonged impacts of sodium glucose cotransporter 2 inhibitors on metabolic dysfunction associated steatotic liver disease in type 2 diabetes a retrospective analysis through magnetic resonance imaging |
| topic | type 2 diabetes mellitus sodium-glucose cotransporter 2 inhibitor metabolic dysfunction-associated steatotic liver disease magnetic resonance imaging-derived proton density fat fraction |
| url | https://www.jstage.jst.go.jp/article/endocrj/71/8/71_EJ24-0005/_html/-char/en |
| work_keys_str_mv | AT agenasuzuki prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT akinorihayashi prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT satoshioda prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT reifujishima prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT naoyashimizu prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT kentamatoba prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT tomomitaguchi prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT takuyatoki prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging AT takeshimiyatsuka prolongedimpactsofsodiumglucosecotransporter2inhibitorsonmetabolicdysfunctionassociatedsteatoticliverdiseaseintype2diabetesaretrospectiveanalysisthroughmagneticresonanceimaging |